{
    "organizations": [],
    "uuid": "25d94dca35d0a52c0169cebae713d696fd845880",
    "author": "",
    "url": "https://www.reuters.com/article/brief-us-fda-clears-pluristems-phase-iii/brief-u-s-fda-clears-pluristems-phase-iii-study-in-treatment-of-muscle-injury-following-hip-fracture-surgery-idUSASC09X9M",
    "ord_in_thread": 0,
    "title": "BRIEF-U.S. FDA Clears Pluristem’S Phase III Study In Treatment Of Muscle Injury Following Hip Fracture Surgery",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - Pluristem Therapeutics Inc:\n* U.S. FDA CLEARS PLURISTEM’S PHASE III STUDY IN TREATMENT OF MUSCLE INJURY FOLLOWING HIP FRACTURE SURGERY\n* PLURISTEM THERAPEUTICS INC - IN DISCUSSIONS WITH SEVERAL EU COUNTRIES TO APPROVE STUDY IN EUROPE\n* PLURISTEM THERAPEUTICS INC - EXPECTS TO BEGIN PATIENT ENROLLMENT IN BOTH EUROPE AND U.S. DURING 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-25T14:06:00.000+03:00",
    "crawled": "2018-04-25T14:22:18.039+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "pluristem",
        "therapeutic",
        "inc",
        "fda",
        "clear",
        "pluristem",
        "phase",
        "iii",
        "study",
        "treatment",
        "muscle",
        "injury",
        "following",
        "hip",
        "fracture",
        "surgery",
        "pluristem",
        "therapeutic",
        "inc",
        "discussion",
        "several",
        "eu",
        "country",
        "approve",
        "study",
        "europe",
        "pluristem",
        "therapeutic",
        "inc",
        "expects",
        "begin",
        "patient",
        "enrollment",
        "europe",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}